Generating real‐world evidence in early Alzheimer's disease: Considerations for applying the target trial emulation framework to study the safety of anti‐amyloid therapies
Little is known about real-world safety of anti-amyloid beta monoclonal antibodies for early Alzheimer's disease.Existing real-world data can support studies of their safety and utilization outcomes.Target trial emulation can guide the design of these studies while minimizing bias.We provide key design and analytical considerations for future studies.
Authors
- Richard Platt (ORCID: https://orcid.org/0000-0002-3248-3583)
- Sonal Singh (ORCID: https://orcid.org/0000-0003-0912-941X)
- Bahareh Rasouli (ORCID: https://orcid.org/0000-0001-8597-993X)
- Ivan H. Abi‐Elias (ORCID: https://orcid.org/0000-0002-9306-7487)
- Jennifer G. Lyons (ORCID: https://orcid.org/0000-0002-5224-0298)
- Noelle M. Cocoros (ORCID: https://orcid.org/0000-0001-7090-2761)
- Jerry H. Gurwitz (ORCID: https://orcid.org/0000-0003-1630-8213)
- Xiaojuan Li (ORCID: https://orcid.org/0000-0002-1305-0846)
Institutions
- Harvard University (US)
- Eastern Virginia Medical School (US)
- University of Massachusetts Chan Medical School (US)
- Harvard Pilgrim Health Care (US)
- Old Dominion University (US)
Publication Details
- Journal
- Alzheimer s & Dementia Translational Research & Clinical Interventions
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/trc2.70080
- Citations
- 2
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 5.26
Funders
- National Institute on Aging